The CRDMO is adding new drug substance and drug product manufacturing capacity in Asia, Europe, and the U.S. — including a 1.74 million-square-foot plant in Delaware.
The GLP-capable facility in Gothenburg expands the company’s global bioanalytical network to support complex therapeutic modalities across drug development.
The CDMO’s development team at its Syracuse Bio Campus will support commercial process development and characterization for Ottimo’s biparatopic antibody.
Join this session to learn how life sciences manufacturers are leveraging advanced flow measurement insights to improve reliability, maintain compliance, and deliver confidence across every batch, cleaning cycle, and critical process.
